Treatment Response Assessment According to Updated PROMISE Criteria in Patients with Metastatic Prostate Cancer Using an Automated Imaging Platform for Identification, Measurement, and Temporal Tracking of Disease

By sjmartinez • November 14, 2024

Benitez CM, Sahlstedt H, Sonni I, Brynolfsson J, Berenji GR, Juarez JE, Kane N, Tsai S, Rettig M, Nickols NG, Duriseti S. Treatment Response Assessment According to Updated PROMISE Criteria in Patients with Metastatic Prostate Cancer Using an Automated Imaging Platform for Identification, Measurement, and Temporal Tracking of Disease. Eur Urol Oncol. 2024 Nov 8:S2588-9311(24)00240-2. doi: 10.1016/j.euo.2024.10.011. Epub ahead of print. PMID: 39521638.

Tags: Artificial intelligence, Automated, Hematology/Oncology, Positron emission tomography, prostate-specific membrane antigen, Publications, Veterans Administration

Related Posts

ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer

Collier AE, Hilz S, Chibly AM, Duan C, Pasquina LW, Sun X, Chavez-MacGregor M, Bardia A, Martín M, Lim E, Sohn J, Pérez-Moreno PD, Fernando[...]

Lentivirus-Based Hematopoietic Stem/Progenitor Cell Therapy Provides Effective and Long-Term Treatment in Hypophosphatasia Mouse Model

Carrillo M, Tomer S, Wang L, Cook E, Wennerberg W, Tien N, Ng H, Alagarsamy J, Rezek V, Martin H, Narisawa S, Millan JL, Crine[...]

Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survival

Marsh LA, Kim TH, Zhang M, Kubalanza K, Treece CL, Chase D, Memarzadeh S, Salani R, Karlan B, Rao J, Konecny GE. Pathologic response to[...]